[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548449":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":42,"centralContacts":46,"locations":57,"responsibleParty":75,"collaborators":41,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":41,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":41,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":60,"whyStopped":41,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"First Affiliated Hospital of Fujian Medical University","OTHER",[8,14,18,23,27,31],{"label":9,"type":10,"description":11,"interventionNames":12},"MIBC diagnostic study-FAPI PET\u002FMRI","EXPERIMENTAL","suspected MIBC participants receive FAPI PET\u002FMRI examination after entering the group.",[13],"Procedure: imaging examinations:FAPI PET\u002FMRI, FDG PET\u002FMRI, MRI",{"label":15,"type":10,"description":16,"interventionNames":17},"MIBC diagnostic study-FDG PET\u002FMRI","suspected MIBC participants receive FDG PET\u002FMRI examination after entering the group.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"MIBC diagnostic study-MRI","ACTIVE_COMPARATOR","suspected MIBC participants receive MRI examination after entering the group.",[13],{"label":24,"type":10,"description":25,"interventionNames":26},"MIBC neoadjuvant evaluation study-FAPI PET\u002FMRI","Patients diagnosed with MIBC receive FAPI PET\u002FMRI examination before and after neoadjuvant therapy.",[13],{"label":28,"type":10,"description":29,"interventionNames":30},"MIBC neoadjuvant evaluation study-FDG PET\u002FMRI","Patients diagnosed with MIBC receive FDG PET\u002FMRI examination before and after neoadjuvant therapy.",[13],{"label":32,"type":20,"description":33,"interventionNames":34},"MIBC neoadjuvant evaluation study-MRI","Patients diagnosed with MIBC receive MRI examination before and after neoadjuvant therapy.",[13],[36],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"PROCEDURE","imaging examinations:FAPI PET\u002FMRI, FDG PET\u002FMRI, MRI","FAPI PET\u002FMRI and FDG PET\u002FMRI examination Data acquisition was performed using a GE Healthcare SIGNA PET\u002FMR instrument. Enrolled patients were injected intravenously with 68Ga-FAPI or 18F-FDG tracer and underwent simultaneous PET and MRI scanning approximately 30-60 minutes after intravenous administration of the tracer at a dose of 1.85-3.7 MBq\u002Fkg.\n\nMRI examination MRI examination was performed using a Skyra 3.0T MRI scanner from Siemens, Germany, with a 16-channel phased-array surface coil, and the scanning range was from the superior margin of the iliac wing to the inferior margin of the pubic symphysis.",[9,15,19,24,28,32],null,[43],{"name":44,"affiliation":5,"role":45},"Xue-Yi Xue, Master","STUDY_CHAIR",[47,53],{"name":48,"role":49,"phone":50,"phoneExt":51,"email":52},"Ning Xu, Doctor","CONTACT","13235907575","0086","drxun@fjmu.edu.cn",{"name":54,"role":49,"phone":55,"phoneExt":51,"email":56},"Xiao-Dong Li, Master","15980273075","lixiaodong@fjmu.edu.cn",[58],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"first hospital affiliated of Fujian medical university","RECRUITING","Fuzhou","Fujian","350005","China","CN",{"type":67,"coordinates":68},"Point",[69,70],119.30611,26.06139,{"lat":70,"lon":69},[73],{"name":74,"role":49,"phone":41,"phoneExt":41,"email":41},"Xu Ning, M.D.",{"type":76,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"PRINCIPAL_INVESTIGATOR","Ning Xu","Deputy Director of Department","100548449","fapi-and-fdg-petmri-in-diagnosis-and-therapy-prediction-of-bladder-cancer-100548449",false,"NCT06421142","FAPI and FDG PET\u002FMRI in Diagnosis and Therapy Prediction of Bladder Cancer","Application Research of FAPI Positron Emission Tomography(PET)\u002FMRI, 18F-Fluorodeoxyglucose (FDG) PET\u002FMRI, and MRI in the Diagnosis of Muscular Invasive Bladder Cancer and Evaluation of Neoadjuvant Therapy Efficacy","Inclusion Criteria:\n\n* Inclusion criteria for MIBC diagnostic studies\n\n  1. Patients with suspected muscle-invasive bladder cancer;\n  2. Completion of FAPI PET\u002FMRI, FDG PET\u002FMRI and MRI;\n  3. Complete clinical laboratory and pathological data.\n* Inclusion criteria for MIBC neoadjuvant therapy efficacy evaluation study\n\n  1. Patients diagnosed with muscle invasive bladder cancer;\n  2. Completion of FAPI PET\u002FMRI, FDG PET\u002FMRI, and MRI before neoadjuvant therapy;\n  3. Complete clinical laboratory and pathological data.\n\nExclusion Criteria:\n\n* Exclusion criteria for MIBC diagnostic study\n\n  1. Combined with other malignant tumors;\n  2. Not receiving surgical treatment;\n  3. Receiving neoadjuvant therapy before surgery;\n  4. Previous allergy to contrast components or similar components;\n  5. Serious organ function abnormalities, such as heart, lung, liver, kidney function serious abnormalities;\n  6. Incomplete clinicopathological data\n* Exclusion criteria of MIBC neoadjuvant therapy efficacy evaluation study\n\n  1. Combination of other malignant tumors;\n  2. FAPI PET\u002FMRI, FDG PET\u002FMRI and MRI were not completed after neoadjuvant therapy;\n  3. Prior hypersensitivity to contrast components or similar components;\n  4. Serious organ function abnormalities, such as serious abnormalities of heart, lung, liver and kidney function;\n  5. Incomplete clinicopathological data.","ALL","18 Years","80 Years",{"count":90,"type":91},80,"ESTIMATED","INTERVENTIONAL",[94],"NA","The aim of this trial is to investigate the value of FAPI PET\u002FMRI, FDG PET\u002FMRI and MRI in diagnosing MIBC and predicting the efficacy of neoadjuvant therapy for MIBC patients, so as to guide the clinic to adjust the treatment plan in time and benefit MIBC patients.",[97],"Urinary Bladder Neoplasms",[99,100],"Neoadjuvant Chemotherapy","Neoplasm Staging","2026-05-28",{"date":103,"type":104},"2026-06-01","ACTUAL",{"date":106,"type":104},"2024-08-02",{"date":108,"type":91},"2029-06-01",{"name":5,"class":6},1]